摘要
目的采用酒精加高脂乳剂建立大鼠脂肪肝模型,通过观察调脂积冲剂对实验大鼠血清总胆固醇(TC)、血清甘油三脂(TG)、血清高密度脂蛋白(HDL-C)、血清低密度脂蛋白(LDL-C)、空腹血糖(FBG)、血清谷氨酸氨基转肽酶(ALT)、血清谷氨酰转肽酶(GGT)、空腹胰岛素(FINS)、肝组织病理及肝指数等指标的检测,并计算胰岛素抵抗指数(HOMA—IR)=FBG~*FINS/22.5。以此探讨调脂积冲剂防治脂肪肝的有效性、可靠性,为进一步研究提供理论依据。
方法将Wistar大鼠52只,于实验室适应性喂养一周后,随机分组共分五组,其中空白对照组、脂肪肝模型对照组、脂肪肝模型易复善治疗组、脂肪肝模型中药调脂积冲剂治疗组、脂肪肝模型中药(六味地黄丸)治疗组。采用酒精合并高脂乳剂建立大鼠脂肪肝模型,以易善复和六味地黄丸为阳性对照,利用全自动生化分析仪中检测TC、TG、HDL-C、LDL-C、ALT、GGT、FBG,采用酶联免疫法测定血清胰岛素含量。胰岛B细胞功能评价采用稳态模式评估法(HOMA),即胰岛素抵抗指数(HOMA—IR)=(FBG)~*FINS/22.5。采用光镜观察组织学变化。
结果模型组TC、TG、LDL-C、ALT、GGT、FBG、FINS、HOMA—IR、肝指数均高于正常组,HDL-C低于正常组。调脂积冲剂能降低肝指数,降低ALT、GGT、TC、TG、LDL-C、FBG、FINS的含量,升高HDL-C的含量,降低HOMA—IR。
结论调脂积冲剂防治脂肪肝的作用机制:
1.调脂积冲剂具有保护肝细胞,稳定和修复细胞膜结构及线粒体等各种肝细胞器的功能,改善肝功能的作用。
2.调脂积冲剂可改善血脂代谢紊乱,防治高脂血症的作用。
3.调脂积冲剂可改善胰岛B细胞的高分泌状态,降低胰岛素分泌量,提高机体对胰岛素的敏感性,改善胰岛素抵抗。
4.调脂积冲剂可降低肝细胞脂肪变性,保护肝组织的作用。
Objective To establish a hepatic fibrosis model in rat according to multiple factors, compound factors rat fatty liver model by observing TiaozhiJi Emulsion on experimental plot in TC,TG,HDL-C,LDL-C,FBG,ALT,GGT,FLNS,the liver and liver pathology index Detection of such indicators,and calculate HOMA-IR = FBG * FINS/22.5.TiaozhiJi Emulsion of this fatty liver of the validity,reliability,and insulin resistance in the formation of fatty liver's role in the process.
Methods 52 Wistar male rats,a week after the laboratory feeding adaptation,randomized divided into five groups,the control group,the control group model of fatty liver,fatty liver model of good easy-treatment group,fatty liver Model medicine TiaozhiJi Emulsion treatment group,fatty liver model of traditional Chinese medicine(Liuwei- dihuang pill) in the treatment group.Combined high-fat emulsion used alcohol fatty liver rat model to Essentiale and Liuweidihuangwan to as a positive control,the use of automatic biochemical analyzer detected TC,TG,HDL-C,LDL-C,ALT and GGT,FBG,using enzyme-linked immunosorbent assay for determination of serum insulin levels.B islet cell function evaluation by homeostasis model assessment(HOMA),or insulin resistance index (HOMA-IR) =(FBG) * FINS/22.5.
Results The TC,TG,LDL-C,ALT and GGT,FBG,FINS,HOMA-IR,liver index were higher than those of the normal group,lower HDL-C group.TiaozhiJi Emulsion can reduce the liver index,lower ALT and GGT,TC,TG,LDL-C,FBG,FINS content,lower HOMA-IR.
Conclusion TiaozhiJi Emulsion control the mechanism of fatty liver:
1.TiaozhiJi Emulsion protect liver cells,and restoration of stability and structure of mitochondrial membrane such as the liver cell functions,and improve liver function.
2.TiaozhiJi Emulsion can improve blood lipid metabolism disorders,prevention and treatment of hyperlipidemia.
3.TiaozhiJi Emulsion can improve islet B-cell secretion of the high state and decrease insulin secretion,improving the body's sensitivity to insulin and improve insulin resistance.
4.TiaozhiJi Emulsion can reduce rat liver liver index,reduced fat deposition in the liver and improve the role of fatty degeneration of the liver
引文
1.历有名,夏维新,主编.脂肪肝现代诊疗.南京:江苏科学技术出版,2003.1,6-10,127-133
2.陈灏珠,主编.实用内科学.第11版.北京:人民卫生出版社,2001.1866-1867
3.Day CP,James OFW.Steatohepatitis:a tale of two"hit"Gastroenterology.1998,114:842 - 845
4.Ludwig J,Viaggiano TR,McGill DB,et al.Nonalcoholic steatohepatitis:Mayo clinic experiences with a hitherto unnamed disease.Mayo Clin proc,1980,55:434 - 438
5.Tsukamoto H,Pe R,Niemela O,et al.Roles of oxidative stress inactivation of Kupffner and Ito cells in liver fibrosis.J Gastroenterol Hepato,1995,10:350-353
6.范建高,曾民德,范竹萍,等.脂肪肝患者临床特点初步探讨.中国实用内科杂志,1998,18(1):37-40
7.王泰龄,刘霞,周元平,等.慢性肝炎炎症活动度及纤维化程度计分方案.中华肝脏病杂志,1998,6(4):195-197
8.陈子馨,王泰龄,赵静波.酒精性大鼠肝损伤中酶组织化学反应的观察.中日友好医院学报,1996,10(3):197-197
9.钟岚,范建高.酒精性脂肪肝性肝炎大鼠模型的建立.中华实用医学杂志,2000,2(1):3-6
10.李东良,郭红哲.大鼠酒精性肝损伤模型的建立及病理学观察.中西医结合肝病学杂志,2000,10(1):30-31
11.孙大裕.脂肪肝动物模型研究进展.中华消化杂志,2002,22(5):305-306
12.段斐,牛建昭,寇素茹,等.复方鳖甲软肝片对大鼠高脂性脂肪肝治疗作用观察.中华实用中西医结合杂志,2004,4(17):2937-2939
13.沈薇.非酒精性脂肪肝的药物治疗.中华肝脏病杂志,2003,11(2):114
14.王江河.脂肪肝的中医辨证分析.中国中西医结合杂志,1999,19(4):245
15.陈国新.六味地黄丸加味治疗脂肪肝64例.陕西中医,2004,25(9):778-779
16.潘智敏,古英,赵丽萍.调脂积冲剂对脂肪肝大鼠治疗作用的实验研究.黑龙江中医药,2004,4(1):46-48
17.雷载权,张廷模主编.《中华临床中药学》.人民卫生出版社,1998
18.李洁,张岱州,高丽霞.中药郁金的现代药理研究.内蒙古中医药,2001,20(1):37-38
19.李峥.郁金的现代研究及临床应用.甘肃科技纵横,2007,36(1):210
20.林秋实.山楂及山楂黄酮预防大鼠脂质代谢紊乱的分子机制研究.营养学报,2000,22(2):131-136
21.洪行球,沃行德,何一中.半夏降血脂作用研究.浙江中医学院学报,1995,19(2):28-29
22.董平,张振清.虎杖中白藜芦醇苷对脂质体脂质过氧化的抑制作用.中国药学杂志.1991,26(6):363-364
23.何熹延.泽泻与高脂血症、动脉硬化和脂肪肝.中国中西医结合杂志,1981,1(2):114-117
24.C.M.Colker,etal.Current therapeutic research,1999,60(3):145
25.中国成人血脂异常防治指南制订委员会.中国成人血脂异常防治指南.中华心血管病杂志,2007,5(35):390-409
26.Marchesini G,Brizi M,Morselli- Labate AM,et al.Alcoholic fatty liver disease with insulin resistance.Am J Med,1999,107:450-5
27.陆伦根,曾民德.改善胰岛素抵抗在非酒精性脂肪肝性肝病防治中的作用.中华肝脏病杂志,2003.11(2):113
1.历有名,夏维新.脂肪肝现代诊疗.南京:江苏科学技术出版社,2003:127-133
2.胡义扬.脂肪肝的中医药治疗-一个值得深入研究的课题.中西医结合肝病杂志,2001,11(3):129-130
3.厉有名,陈卫星,虞朝辉,等.浙汀省酒精性肝病流行病学调查概况.中华肝脏病杂志,2003,11(1):643-649
4.Kumar KS,Malet PF.Nonalcoholic steatohepatitisl.Mayo Clin Proc,2000,75(7):733-739
5.James O,Day C.Nonalcoholic steatohepatitis,another diasease of affluence,Lancet,I999,353(9165):1634-1636
6.Manton ND,Lipsett J,Moore DJ,et al.Nonalcoholic steatohepatitis in children and adolescents.Med J Aust,2000,173:476-9
7.Assy N,Kaita K,Mymin D,et al.Fatty infiltraion of liver in hyperlipidemic patients.Dig DisSci,2000,45:1929-34
8.陆再英.普通高等教育“十五”国家级规划教材、全国高等学校教材.内科学.第6版.北京:人民卫生出版社,2004,821-831,832-836
9.Sheth SG,Gordon FD,Chopra S.Nonalcoholic steatohepatiits.Ann Intern Med,1997,126:137-145
10.Schaffner F,Pockros PJ,Esrason KT.Nonalcoholic fatty liver.In Haubr ich W,Schaffner F,Beek JE.eds.Bocus Gastroenterology.5thed.W.B.Saunders Company,1995,3:2246-2276
11.Pinto HC,BaptistaA,Cailo ME,et al.Nonalcoholicsteatohepatiits:Clinocopathological comparison with alcoholic hepatitis in ambulatory andhospitalized patients.Dig Dis Sci,1996,41(1):172-179
12.French SW,Nash J,Shittaba P,et al.Pathology of alcoholic liver disease.Semin Liver Dis,193,13:15
13.范建高,李继强,曾民德.脂肪肝与纤维化的关系及其机制.国外医学消化分册,1997,17(2):92-95
14.Sanyal AJ,Campbell - Sargent C,Mirshahi F,et al.Fatty liver an additional and treatable feature of the insulin resistance syndrome.Q J Med,1999,29:166
15.Ludwig J,Viaggiano TR,McGill DB,et al.Nonalcoholic steatohepatitis:Mayo clinic experiences with a hitherto unnamed disease.Mayo Clin Proc,1980,55:434-438
16.Pinto HC,Baptista A,Cailo ME,et al.Nonalcoholic steatohepatiits:Clinocopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients.Dig Dis Sci,1996,41(1):172-179
17.范建高,曾民德,李继强,等.肝内脂肪、脂质过氧化与肝纤维化关系的实验研究.中华内科杂志,1997,36912):808-811
18.Tsukamoto H,pe R,Niemela O,et al.Roles of oxidative stress inactivation of Kupffner and Ito cells in liver fibrosis.J Gastroenterol Hepato,1995,10:350-353
19.王春华,陈东风.线粒体膜通透性转化孔在非酒精性脂肪肝肝细胞凋亡中的作用.重庆医学,2007,36(8):714-715
20.范建高,曾民德,洪健,等.不饱和脂肪酸对L202和HLF细胞增殖及细胞外基质合成的影响.华人消化杂志,1998,6(6):502-504
21.Pinto HC,Baptista A,Cailo ME,et al.Nonalcoholic steatohepatiits:Clinocopathological comparison with alcoholic hepatitis in ambulatory andhospitalized patients.Dig Dis Sci,1996,41(1):172-179
22.谢敏卿,付丽蓉.脂肪肝的中医药治疗.光明中医,1998,13(6):18
23.郭秀丽.非酒精性脂肪肝发病机制.医师进修杂志,2005,9(28):53-55
24.LiZ,Soloski MJ,Diehl AM.Dielary factors alter hepatic innate immune system in mice with nonalcohllic fatty liver disease.Hepatology,2005,42:880-885
25.Medina EA,Erichson KL,Stanhope KL,et al.Evidence that tumor necrosis factor alpha-induced hyperinsulinemia prevents decreases of circulating leptin durinn fastinn in rat.Metabolism,2002,51..1104-1110
26.Crespo J,II iktr M N,Esqui M,et al.Gene expression of tumer necrosis actor alpha and TNF-recptors、 p55 and p75in nalcoholicsteatohepatitispatiens Hepatology,2001,34(6):1185-1193
27.Senn JJ,Klover PJ,Now ak IA,et al.Interleukin induces cellular insulin resistance in hepatocytes.Diabetes,2002,51::3391-3399
28.Stefan N,Stumvoll M.Adiponectin- its role in metabolism and beyond Hom Metab Res, 2002,34(9):469-474
29.范建高,曾民德,李继强,等.血清胆碱酯酶诊断脂肪肝价值的再探讨.肝脏,1996,1(4):215-217
30.范建高.肝活检在脂肪肝诊断中的作用.中华肝脏病杂志,2000,8:116
31.陈建国.脂肪肝的研究近况.中医药导报,2005,11(5):83-85
32.范建高,曾民德月旨肪肝的研究进展.胃肠病学和肝病学杂志,1999,8(2):149-155
33.Sheth SG,Gordon FD,Chopra S.Nonalcoholic steatohepatiits.Ann In-tern Med,1997,126:137-145
34.王伯祥.中医肝胆病学.北京:中国中医药科技出版社,1995:44
35.司晓晨,陈文垲,卑其斯.益肾降脂片治疗脂肪肝34例疗效分析.江苏中医,1996,17(7):8-9
36.刘燕玲.浅谈脂肪肝的中医药治疗.北京中医药大学学报,1995,18(5):54
37.王丽萍,沈国良.益肾消脂汤治疗脂肪肝30例.浙江中医杂志,2001,36(6):241
38.李勇,王杰,孙建芝.肝脂清治疗脂肪肝100例.山东中医杂志,2000,19(6):343-344
39.王江河.脂肪肝的中医辨证分析.中国中西医结合杂志,1999,19(4):245
40.金群.中医分型辨治脂肪肝76例.江苏中医,1997,18(8):10
41.吴益萍.辨证分型治疗脂肪肝87例.实用中医药杂志,2000,16(7):14
42.周琴花.脂肪肝的中医病因病机证候探讨.中医文献杂志,1998,(1):19
43.裴道灵.舒肝健脾法治疗老年脂肪肝临床观察.四川中医,2001,19(6):28-29
44.潘智敏.脂肪肝病机及治疗研析.浙江中医杂志,2004,1:8-9
45.王丽萍,沈国良.益肾消脂汤治疗脂肪肝30例.浙江中医杂志,2001,36(6):241
46.张桂芬.中药祛脂护肝汤治疗脂肪肝的临床研究.四川中医,2003,21(9):32-33
47.李来秀,周若梅,张智勇.调脂化瘀丸治疗脂肪肝112例.浙江中医杂志,2004(2):93
48.陈建宗.降脂保肝汤治疗老年脂肪肝34例.安徽中医学院学报,1998,17(6):25-26
49.吴继勇.彭胜权教授治疗肝病经验.新中医,2000,32(11):8-9
50.张桂芳.中药去脂护肝治疗脂肪肝的临床研究.四川中医2003,21(9):32-33
51.曾红钢.调脂保肝汤治疗脂肪肝65例.中西医结合肝病杂志,2002,12(2):118-119
52.刘三都,舒德云,杨庆坤,等.肝脂灵汤治疗脂肪肝126例.中西医结合肝病杂志, 2003,13(6):370-371
53.林宏.降脂柔肝汤治疗脂肪肝68例.中西医结合肝病杂志,2003,13(5):301-302
54.冯立.化痰理肝方治疗脂肪肝60例.中西医结合肝病杂志,2001,11(5):304-30
55.杨钦河,陈学银,徐云生.降脂宁肝胶囊治疗脂肪肝53例.新中医,2003,35(4)53
56.黄朝.舒肝降脂煎治疗脂肪肝的临床观察.上海中医药杂志,2003,37(9):10-11
57.郑宋明,郑晶晶.金蟾疏肝散治疗脂肪肝107例临床观察.中国中西医结合杂志,2003,23(12):929-930
58.潘智敏.调脂积冲剂对脂肪肝大鼠治疗作用的实验研究.黑龙江中医药,2005,4:46-48
59.李文彪,王毅仁.清源调脂胶囊治疗高脂血症性脂肪肝实验研究.中西医结合肝病杂志.2001,11(3):159-161
60.陈银华,雷陵,张茂林.神农肝脂宁对大鼠实验性脂肪肝的影响.中西医结合肝病杂志,2003,13(4):221-22
61.祁培宏,余莉芸,刘平.消脂保肝饮抗大鼠脂肪肝作用的研究.中西医结合肝病杂志,2000,10(5):33-35
62.张风华,黄敏,王大利.灵芪复方胶囊预防治疗脂肪肝的实验研究.医学理论与实践,2004,17(3):253-255